Alpha Cognition Inc. (ACOGF)
Market Closed
24 Dec, 20:00
OTC PINK OTC PINK Primary $
5. 03
0
0%
$
35.63M Market Cap
- P/E Ratio
0% Div Yield
15,902 Volume
- Eps
$ 5.03
Previous Close Day Range
4.95 5.03
Year Range
4.66 18.5
Want to track ACOGF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
ACOGF Chart
Alpha Cognition Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Michael E. McFadden B.B.A. CEO | OTC PINK Exchange | - ISIN |
| Canada Country | - Employees | - Last Dividend | 5 Nov 2024 Last Split | - IPO Date |
Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
Contact Information
Address: 750 West Pender Street
Phone: 604-564-9244
Website: https://www.alphacognition.com
2024 © Marketlog. All Rights Reserved.
